

20 November 2025

ASX Announcement

US Government affairs group appointed to advance biodefence and health security opportunities

- **Appointment of leading Washington DC-based government affairs firm, Todd Strategy Group (TSG) to accelerate US government engagement**
- **TSG has a collective 60 years' experience in the US government – Principals include former senior BARDA, ASPR and HHS officials**
- **Engagement initiatives to focus on advancing Island's reach across the US biodefence and health security landscape**
- **Underpins Island's strategy to position Galidesivir as a critical counter measure against high-priority viral threats including Marburg**
- **Follows strong response from the US FDA confirming Animal Rule path and Priority Review Voucher applicability**
- **Strengthens commercial readiness protocols ahead of clinical trial commencement and pending FDA interactions**

MELBOURNE Australia, 20 November 2025: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to advise it has initiated a collaboration with Todd Strategy Group ("TSG"), a Washington, DC-based health policy and medical countermeasures consulting firm to assist the Company in navigating the US biodefence and health security landscape as it advances its antiviral programs.

The engagement is focused on strengthening Island's awareness around federal priorities, regulatory trends, and policy developments that inform national preparedness efforts, as well as assisting in identifying non-dilutive funding strategies.

TSG is a federal government affairs and strategic consulting firm based in Washington DC. The group specialise in providing legislative, regulatory guidance and advocacy for clients pursuing federal government healthcare programs. Personnel include former senior-level government officials with a combined 60 years' experience in the US federal government, which includes senior roles on key congressional committees.

Island will be working alongside TSG's Health Policy and Medical Countermeasures Principal, Taylor Sexton. Mr Sexton was previously a Senior Advisor to the Assistant Secretary for Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS) through the COVID-19 pandemic. While at HHS he advised the ASPR on critical issues including the development and execution of Operation Warp Speed to accelerate development, manufacturing and distribution of COVID-19 therapeutics, diagnostics and vaccines.

As part of the partnership, TSG will provide strategic context on federal processes, agency activities, and congressional considerations relevant to the broader medical countermeasure enterprise. This support is designed to ensure Island remains well-informed and appropriately positioned as its programs progress and as the US Government continues to refine its priorities across emerging infectious disease threats.



Commentary:

CEO and Managing Director, Dr David Foster said: *“Appointing TSG comes at a pivotal time in Galidesivir’s development and marks a major step in accelerating Island’s opportunity to commence US government engagement. Their deep expertise and extensive relationships across the broader medical countermeasure ecosystem will provide access to decision makers, processes and the potential non-dilutive funding pathways that will assist with our stated strategy.”*

“With the viability of a regulatory path under the FDA’s Animal Rule now confirmed for Marburg countermeasures and Galidesivir positioned to generate a Priority Review Voucher, our focus will now shift to executing on the next phase of clinical development, while pursuing opportunities to obtain US Government support.”

“We look forward to working closely with TSG and Taylor to build further momentum across regulatory, clinical and commercial preparedness initiatives in the US.”

- Ends -

Approved for release to the ASX by:

David Foster (CEO and Managing Director)
Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company’s share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company’s website.

Visit www.islandpharmaceuticals.com for more on Island.